This report from Life Science Intelligence provides the latest market data for the Global Cell Delivery Catheters Market. Information covered by this report includes:
The global market for cell delivery catheters was valued at an estimated $310 million in 2020 and is projected to increase at a CAGR (2020-2024) of 1.3%. The report covers the delivery catheters for use in cellular therapy procedures.
This report covers the impact of COVID-19 on the cell delivery catheters market, including a recent forecast from 2020 to 2024. COVID-19 has also impacted leading competitors, such as Boston Scientific, Johnson & Johnson, and Medtronic, and others. The report provides insights into trends, drivers, and limiters of the cell delivery catheters market, as well as highlights potential opportunities.
The global cell delivery catheters market was negatively impacted by the COVID-19 pandemic. The pandemic has slowed down the pace of clinical clinical research where these cellular delivery catheters are predominantly being utilized. The market is expected to recover to pre-COVID-19 levels in 2021.
Advancements in biologics have led to more than 1,000 cell and gene therapies that are in various stages of development to treat oncological disorders, cardiovascular disorders, and neurological disorders. Immunotherapies, stem cells, and gene therapies have to be administered in a targeted, micro-dosed, and periodic manner. The targeted, controlled and prolonged drug delivery is being achieved through the cell delivery catheters.
Boston Scientific, Johnson & Johnson, and Medtronic are the leading companies in the development of cell delivery catheters. TRI Medical and BioCardia are other companies with a significant market presence.